Abstract
Lung cancer is the leading cause of cancer-related mortality in the US. Although an improvement in outcome is possible with the continued advancement of cytotoxic-based treatment, clinical research is currently focused on utilising novel molecular targets with proven efficacy in preclinical models and a low toxicity profile. This is the result of advances in understanding of tumour biology and molecular pathways that have been implicated in cancer pathogenesis and progression. Novel agents targeting cell cycle regulation, angiogenesis and signal transduction pathways have reached clinical testing in lung cancer and are discussed in this review.
MeSH terms
-
Alkyl and Aryl Transferases / antagonists & inhibitors
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use
-
Carcinoma, Small Cell / drug therapy
-
Carcinoma, Small Cell / genetics
-
Carcinoma, Small Cell / immunology
-
Clinical Trials as Topic
-
Cyclooxygenase 2
-
ErbB Receptors / antagonists & inhibitors
-
Farnesyltranstransferase
-
Genetic Therapy
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Lung Neoplasms / therapy*
-
Membrane Proteins
-
Prostaglandin-Endoperoxide Synthases
-
Protease Inhibitors / therapeutic use
-
Signal Transduction
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Cancer Vaccines
-
Isoenzymes
-
Membrane Proteins
-
Protease Inhibitors
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Alkyl and Aryl Transferases
-
Farnesyltranstransferase
-
ErbB Receptors